Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 6, 2012, Pages 337-343

  Dillman, Robert O ^a   Barth, Neil M ^a   Vandermolen, Louis A ^a   Mahdavi, Khosrow ^a   McClure, Stephanie E ^a  

^a Hoag Family Cancer Institute   (United States)

Author keywords

IL2; long term survival; metastatic melanoma

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; IMATINIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; PACLITAXEL; PEGINTERFERON; PEGINTERFERON ALPHA; SORAFENIB; TEMOZOLOMIDE; VEMURAFENIB; VINBLASTINE;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84864040339     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1220     Document Type: Article

References (37)

1. Siegel R, Naishadhma D, Ahmedin J. Cancer statistics, 2012. Cancer J Clin 2012;62:10.
2. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011;26:1.
3. Dillman RO, Church C, Oldham RK, et al. Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients. Cancer 1993;71:2358.
4. Dillman RO, Weismann MC, VanderMolen LA, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 inpatients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group. Cancer Biother Radiopharm 1997;12:249.
5. Dillman RO, Schiltz P, DePriest C, et al. Tumor-infiltrating lymphocytes and interleukin-2: Dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 2004;19:730.
6. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or highdose interleukin-2 alone. N Engl J Med 1987;316:889.
7. West WH, Tauer KW, Yannelli JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898.
8. Dillman RO. What to do with IL-2? Cancer Biother Radiopharm 1999;14:423.
9. Dillman RO, Barth NM, Vandermolen LA, et al. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm 2011;26:273.
10. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105.
11. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993;11:1969.
12. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158.
13. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748.
14. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711.
15. Robert C, Thomas LO, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated melanoma. N Engl J Med 2011;364:26.
16. Chapman PB, Hauschild, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507.
17. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as secondline treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823.
18. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2011;30:34.
19. Dummer R, Garbe C, Thompson JA, et al. Randomized doseescalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24:1188.
20. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707.
21. Miller RL, Steis RG, Clark JW, et al. Randomized trial of recombinant a2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989;49:1871.
22. Chapman PB, Einhorn LH, Meyers MI, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745.
23. Johnston SR, Constenla DO, Moore J, et al. Randomized phase II trial of BCDT [carmustine (BCNU) cisplatin, dacrabazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998;77:1280.
24. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 2002;20:2045.
25. Bedikian AY, Johnson MM, Warneke CL, et al. Systemic therapy for unresectable metastatic melanoma: Impact of biochemotherapy on long-term survival. J Immunotoxicol 2008;5:201.
26. Minor DR, Moore D, Kim C, et al. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist 2009;14:994.
27. Dillman RO, Crispin R, Oldham RK. The Cancer Biotherapy Research Group [CBRG], (formerly the National Biotherapy Study Group [NBSG]): A 10-year perspective. Cancer Biother Radiopharm 1997;12:229.
28. Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25:3802.
29. Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer. Molec Biother 1992;4:4.
30. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994;9:183-209.
31. Flaherty KT, Puzanov I, KimKB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809.
32. Solit DB, Rose N. Resistance to BRAF inhibition in melanoms. N Engl J Med 2011;364:772.
33. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411.
34. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immunerelated response criteria. Clin Cancer Res 2009;15:7412.
35. Dillman RO, Church C, Barth NM, et al. Long-term survival after continuous infusion interleukin-2. Cancer Biother Radiopharm 1997;12:243.
36. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904.
37. Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med 2012; 366:866.